BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. [DOI: 10.2217/imt-2021-0168] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Van Scoy LJ, Duda SH, Scott AM, Baker A, Costigan H, Loeffler M, Sherman MS, Brown MD. A mixed methods study exploring requests for unproven COVID therapies such as ivermectin and healthcare distrust in the rural South. Prev Med Rep 2023;31:102104. [PMID: 36619802 DOI: 10.1016/j.pmedr.2022.102104] [Reference Citation Analysis]
2 Chavda VP, Bezbaruah R, Dolia S, Shah N, Verma S, Savale S, Ray S. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. Process Biochemistry 2023. [DOI: 10.1016/j.procbio.2023.01.018] [Reference Citation Analysis]
3 Coyle L. Celebrating the 15th anniversary of Immunotherapy: a reflection on 2022. Immunotherapy 2023;15:1-4. [PMID: 36700701 DOI: 10.2217/imt-2022-0291] [Reference Citation Analysis]
4 Chavda VP, Ping FF, Chen ZS. An Impact of COVID-19 on Cancer Care: An Update. Vaccines (Basel) 2022;10. [PMID: 36560482 DOI: 10.3390/vaccines10122072] [Reference Citation Analysis]
5 Chavda VP, Patel AB, Vora LK, Singla RK, Shah P, Uversky VN, Apostolopoulos V. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. Curr Pharm Des 2022;28:3658-70. [PMID: 36284382 DOI: 10.2174/1381612829666221024124848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chavda VP, Redwan EM. SARS-CoV-2: Immunopeptidomics and Other Immunological Studies. Vaccines 2022;10:1975. [DOI: 10.3390/vaccines10111975] [Reference Citation Analysis]
7 Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines 2022;10:1926. [DOI: 10.3390/vaccines10111926] [Reference Citation Analysis]
8 Jansen-van Vuuren RD, Jedlovčnik L, Košmrlj J, Massey TE, Derdau V. Deuterated Drugs and Biomarkers in the COVID-19 Pandemic. ACS Omega 2022. [DOI: 10.1021/acsomega.2c04160] [Reference Citation Analysis]
9 Kulesza J, Kulesza E, Koziński P, Karpik W, Broncel M, Fol M. BCG and SARS-CoV-2-What Have We Learned? Vaccines (Basel) 2022;10:1641. [PMID: 36298506 DOI: 10.3390/vaccines10101641] [Reference Citation Analysis]
10 Catalano A, Iacopetta D, Ceramella J, Maio AC, Basile G, Giuzio F, Bonomo MG, Aquaro S, Walsh TJ, Sinicropi MS, Saturnino C, Geronikaki A, Salzano G. Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment? Foods 2022;11:2884. [PMID: 36141012 DOI: 10.3390/foods11182884] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chavda VP, Kumar A, Banerjee R, Das N. Ayurvedic and Other Herbal Remedies for Dengue: An Update. Clinical Complementary Medicine and Pharmacology 2022;2:100024. [DOI: 10.1016/j.ccmp.2022.100024] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Assmus F, Driouich JS, Abdelnabi R, Vangeel L, Touret F, Adehin A, Chotsiri P, Cochin M, Foo CS, Jochmans D, Kim S, Luciani L, Moureau G, Park S, Pétit PR, Shum D, Wattanakul T, Weynand B, Fraisse L, Ioset JR, Mowbray CE, Owen A, Hoglund RM, Tarning J, Lamballerie X, Nougairède A, Neyts J, Sjö P, Escudié F, Scandale I, Chatelain E. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. Microorganisms 2022;10:1639. [PMID: 36014057 DOI: 10.3390/microorganisms10081639] [Reference Citation Analysis]
13 Chavda VP, Haritopoulou-Sinanidou M, Bezbaruah R, Apostolopoulos V. Vaccination efforts for Buruli Ulcer. Expert Rev Vaccines 2022. [PMID: 35962475 DOI: 10.1080/14760584.2022.2113514] [Reference Citation Analysis]
14 Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. IJMS 2022;23:8606. [DOI: 10.3390/ijms23158606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Islamie R, Iksen I, Buana BC, Gurning K, Syahputra HD, Winata HS. Construction of network pharmacology-based approach and potential mechanism from major components of Coriander sativum L. against COVID-19. PHAR 2022;69:689-697. [DOI: 10.3897/pharmacia.69.e84388] [Reference Citation Analysis]
16 Chavda VP, Chhabria MT, Apostolopoulos V. Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics 2022;2:165-70. [DOI: 10.3390/biologics2030013] [Reference Citation Analysis]
17 Chavda VP, Soni S, Prajapati R, Yallapu MM, Apostolopoulos V. Reply to the letter 'Effectiveness of COVID-19 vaccines against Omicron variant'. Immunotherapy 2022. [PMID: 35787091 DOI: 10.2217/imt-2022-0135] [Reference Citation Analysis]
18 de Oliveira Campos DM, da Silva MK, Silva de Oliveira CB, Fulco UL, Nobre Oliveira JI. Effectiveness of COVID-19 vaccines against Omicron variant. Immunotherapy 2022. [PMID: 35787018 DOI: 10.2217/imt-2022-0077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Krishnan A, Gangadaran P, Chavda VP, Jogalekar MP, Muthusamy R, Valu D, Vadivalagan C, Ramani P, Laishevtcev A, Katari NK, Ahn BC. Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp Biol Med (Maywood) 2022;247:1244-52. [PMID: 35549570 DOI: 10.1177/15353702221092984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM, Apostolopoulos V. Therapeutics to tackle Omicron outbreak. Immunotherapy 2022. [PMID: 35678049 DOI: 10.2217/imt-2022-0064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
21 Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
22 Huang Z, Chavda VP, Vora LK, Gajjar N, Apostolopoulos V, Shah N, Chen Z. 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Front Pharmacol 2022;13:899633. [DOI: 10.3389/fphar.2022.899633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
23 Chavda VP, Bezbaruah R, Athalye M, Parikh PK, Chhipa AS, Patel S, Apostolopoulos V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022;14:759. [DOI: 10.3390/v14040759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
24 Chavda VP, Apostolopoulos V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines 2022;10:367. [DOI: 10.3390/vaccines10030367] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
25 Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, Chen ZS. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep 2022;74:1120-48. [PMID: 36214969 DOI: 10.1007/s43440-022-00425-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]